Annual report
Announcement under Regulation 30 (LODR)-Newspaper Publication 26 Aug - Newspaper publication regarding the completion of dispatch of 9th AGM Notice and Annual report
Source: Bse
Solara Active Pharma Sciences Limited (SOLARA)
Small CapHealthcare stocks · Small cap · NSE
Solara Active Pharma Sciences Limited operates in API / Pharma, within the Healthcare sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.
Data qualityFresh enough for analysisQuote updated 21 Oct, 03:31 pm ISTDetails
Quote21 Oct, 03:31 pm IST
Base fundamentals06 Oct 2026 · screener
Latest result23 Jul, 06:53 pm IST
Score21 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags04 Jun 2026
Coverage14/14 · 100%
Valuation2026-07-20 · Rf 6.8% · Healthcare P/E 22.0 (n=1)
Technical timing lens
Trend score and candlestick chart
67BullishSMA20 +2.2% / mo · MACD −
Stock trend: 61
Sector RS: 76
Sector 3M: -5.2% vs Nifty 500 -5.6%
Healthcare FPI tailwindFlow only
FPI equity flow was positive in both fortnights, but the sector index is below its 100-session average. View sector evidence
Technical chart
SOLARAD candles · FIT view+34.1%Latest close ₹648.25 on 2026-10-21
Bar
+1.1%
RSI
45
MACD hist
-7.73
52W pos
64%
2026-10-21O ₹641.00H ₹656.40L ₹633.25C ₹648.25Vol 6.1L sh
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
SOLARANifty Healthcare IndexNifty 500
- SOLARA
- +16.0%
- Nifty 500
- -6.5%
- Nifty Healthcare Index
- -6.3%
- Vs Nifty 500
- +22.5 pp
Chart stats
21 Oct 2026- From 52W high
- -16.2%
- 52W range position
- 64%
- ATR (14)
- 7.0%
- Volume vs 20D
- 1.05x
- Avg traded value
- ₹40.7 Cr
- 20D price channel
- ₹525.2 - ₹767.9
₹774
₹422 - ₹774
₹45.1
Latest completed session
20-session average
50.9% annualized volatility
Research snapshot
What the evidence says now
Weak fundamentals, while price trend supports entry. This looks more like momentum/speculation than a clean fundamental investment setup.
Weak U-Score but strong trend: momentum may be ahead of fundamentals.
Suggested next step
Momentum only
Trend is strong but fundamentals do not support a clean investment thesis.
U-Score
Legacy · OVERVALUED18
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Good67
Revenue +19.8% · PAT +45.5% YoY
Technical
Bullish67
Price trend and sector-relative-strength timing.
Valuation
Legacy model-23345.1%
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Limited evidence57
Financial-only signal; management claim evidence is not sufficient yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 30 Jun 2026
Good · 67/100Rev +20% YoY · PAT +45% YoY · operating leverage · margin compression
Filed 23 Jul 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹382 Cr | +19.8% | -1.3% |
| EBITDA | ₹62 Cr | +8.8% | +6.9% |
| Operating margin | 16.0% | -200 bps | +100 bps |
| PAT | ₹16 Cr | +45.5% | +60.0% |
| PAT margin | 4.2% | +74 bps | +161 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- 769.00
- P/B
- 1.96
- EV/EBITDA
- 13.46
- Market Cap
- 3285.00Cr
Profitability
- ROE
- -0.13%
- ROCE
- 4.86%
- ROA
- -0.09%
- Dividend Y
- —
Growth (CAGR)
- Revenue 5Y
- -3.00%
- EPS 5Y
- -13.00%
- Revenue 3Y
- -2.00%
- EPS 3Y
- 25.00%
Balance Sheet
- Debt/Equity
- 0.55
- Interest Coverage
- 2.09×
- Altman Z
- 3.63
- Book Value
- 346.00
Cash Flow
- FCF Yield
- 1.64%
- FCF Positive Y
- 6/5
- OCF
- 153.00 Cr
- EPS TTM
- -1.58
Shareholding
- Promoter Hold
- 41.93%
- Promoter Pledge
- 37.10%
- Momentum 52W
- 72%
Financial History
Updated 20/10/2026
Revenue
₹ CrLatest: 1,369+6.6% vs prev
Net Profit
₹ CrLatest: -7.0-800.0% vs prev
Return on Equity
%Latest: -0.6-722.2% vs prev
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
NeutralTrend is undirectional — long-term uptrend intact. RSI 45.
- Price above SMA200 (long-term uptrend) but mid-term MAs not aligned.
- SMA20 rising (~2.1% over last month) — short-term momentum positive.
- RSI(14) at 45 — sideways, no extreme reading.
- MACD below signal but histogram contracting — bearish momentum easing.
- 16% off 52W high · 54% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Nifty 500 leadership
Relative Strength & Trend Stage
80
RS percentile
Stage 2 UptrendEstablished S2
1M return
-13.9%
3M return
+16.0%
6M return
+30.0%
1Y return
+8.8%
RS 1D
+2
RS 20D
-3
Sector rank
-
Industry rank
-
Stage evidence
- Price is 13.8% above the 30-week proxy.
- The 50-DMA is above the 30-week proxy and its slope is rising +5.8%.
- Both 3-month and 6-month returns are positive.
50-DMA
price below
200-DMA
price above
S2 entered
31 Aug 2026
S2 age
35 trading sessions
Sector
unranked
Industry
unranked
Relative-strength line vs Nifty 500 (base 100)
262 observations
21 Oct 2026Value 109.29+1.34%
RS vs Nifty 500109
Valuation & peers
U-Score 18 · legacy U-Score band OVERVALUED · valuation evidence and comparable companies
Valuation & peers
U-Score 18 · legacy U-Score band OVERVALUED · valuation evidence and comparable companies
OVERVALUED
Fundamental score breakdown
U band · OVERVALUEDValuation4/30
Growth2/25
Quality0/20
Balance Sheet4/15
Cash Flow5/10
Piotroski
5/9 (+3)
Penalties
0
Raw sum
18
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
18/100 · legacy band OVERVALUED
Positive drivers
- Cash flow contributes 5/10 to the score.
- Balance sheet contributes 4/15 to the score.
- Valuation contributes 4/30 to the score.
Main drags
- Promoter pledge is 37.1%.
- Fair-value margin of safety is negative at -23345.1%.
- Quality is weaker at 0/20; verify the latest quarterly trend.
Sector valuation model
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
769.0
PB
2.0
EV/EBITDA
13.5
ROE
-0.1%
ROCE
4.9%
FCF Yield
1.6%
Debt/Equity
0.6
MoS
-23345.1%
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 21 Oct 2026
v4.3-runtime-valuation
Final score
18
Previous: 14 (+4)
Legacy U-Score band
OVERVALUED
Previous: OVERVALUED
Margin of safety
-23345.1%
Previous: -23345.1%
Score history
12 stored score snapshots. Latest stored move: +0 points.
21 Oct 2026
v4.3-runtime-valuation
14
14
14
14
14
14
14
14
14
14
14
14
Factor attribution
Valuation
4+3
was 1
Balance sheet
4+1
was 3
Modelled fair value
Graham Number
—
Growth-justified P/E
3.3
Growth-justified Value
—
-23345.1% MoS
PEG
—
Comparable companies
Peers
Business-comparable peers in Healthcare — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
KPL
Small
Kwality Pharmaceuticals Limited
Healthcare Services
match 83
54
46.3
22.6%
+4%
FAIR VALUE
SMSPHARMA
Small
SMS Pharmaceuticals Limited
Healthcare Services
match 83
35
43.7
14.3%
-27%
WATCHLIST
INDSWFTLAB
Small
Ind-Swift Laboratories Limited
Pharmaceuticals
match 82
34
51.5
4.0%
-16%
WATCHLIST
HIKAL
Small
Hikal Limited
Pharmaceuticals
match 81
30
62.4
2.2%
-3367%
OVERVALUED
INDOCO
Small
Indoco Remedies Limited
Healthcare Services
match 81
18
—
-9.4%
-10580%
OVERVALUED
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Issuer presentation review pending
Solara Active Pharma Sciences Limited operates in API / Pharma, within the Healthcare sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 30 Jun 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.
Trust Score
57Limited evidence · low confidenceTrust Lite
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 20th percentile of the scored universe and 100th percentile within Healthcare. Main check: promoter alignment is weak at 35/100.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Computed 05 Sept 2026
management-trust-v1
61 docs text-extracted · 35 concalls text-extracted
Score band
Limited evidence
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
Relative rank
20th percentile
overall median 67 · Healthcare: 100th pctile, median 57 · Small: 23rd pctile, median 66
Evidence depth
Financial-only
61 documents have extracted text, but claim history is not strong enough yet.
Claim delivery
Outcome history still building
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Limited evidence · low confidenceWhat it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Needs extra due diligence; demand valuation comfort and recent improvement.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
35
weak · holding, pledge, alignment
Cash flow
77
strong · profit to cash conversion
Balance sheet
73
acceptable · leverage and solvency
Discipline
40
weak · capital discipline
Results
53
watch · quarterly consistency
Trust positives
- ▸FCF yield is positive at 1.8%.
- ▸6 years of positive FCF.
- ▸3/4 latest quarters had positive YoY revenue growth.
Trust risks
- ▸Promoters have pledged 37.1% of holding.
- ▸2 latest quarters had PAT decline worse than 25% YoY.
- ▸ROCE is low at 4.9%.
- ▸ROE is low at -0.1%.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Continue researching Solara Active Pharma Sciences Limited
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
Announcement
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS 18 Aug - Solara Active Pharma Sciences Limited has informed regarding allotment of 2250 equity shares pursuant to exercise of ESOP options
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 24 Jul - Solara Active Pharma Sciences Limited has informed about the copy of the Newspaper publication providing extract of the unaudited Financial Results (Standalone and Consolidated) ....
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 9 Jul - Copy of newspaper publication with respect to Final Reminder cum Forfeiture Notice for payment of Call money to partly paid equity shareholders
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 26 Jun - Copy of newspaper advertisement regarding dispatch of notices to shareholders for the transfer of equity shares to the IEPF in respect of the unclaimed and …
Source: Bse
Credit rating
Announcement under Regulation 30 (LODR)-Credit Rating 23 Jun - CRISIL upgraded Solara's Rs.791.2 crore bank facilities to BBB+/Stable and A2.
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS 16 Jun - Allotment of 2,250 Equity shares pursuant to exercise of Options under Solara Employee Stock Option Plan 2018
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS 16 Jun - Allotment of 70,000 Equity Shares pursuant to exercise of Options under Solara Employee Stock Option Plan 2024
Source: Bse
Annual report
Annual Report 2026
Source: Bse
Annual report
Annual Report 2026
Source: Bse
Annual report
Annual Report 2025
Source: Bse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.